DOI: 10.1001/jama.2026.19125 ISSN: 0098-7484

Peptides, FDA’s Pharmacy Compounding Advisory Committee, and the Future of FDA Drug Approval

Sophia Samantaroy, Isabella Xu, Peter Lurie
Show PDF Cite

This Viewpoint discusses the US Food and Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee’s recommendation to add 7 peptides to the compounding 503A Bulks List and the profound threat that compounding these peptides could represent to the drug-approval process and patients.

More from our Archive